Denali Therapeutics Inc. has announced upcoming presentations of clinical and preclinical data from its Enzyme Transport Vehicle™ $(ETV)$ programs at the 22nd Annual WORLDSymposium™, scheduled for February 2-6, 2026, in San Diego, California. The presentations will cover continued follow-up from the Phase 1/2 study of tividenofusp alfa (DNL310) for Hunter syndrome (MPS II), preliminary clinical data from the ongoing Phase 1/2 study of DNL126 (ETV:SGSH) for Sanfilippo syndrome type A (MPS IIIA), and the Phase 1 study design of DNL952 (ETV:GAA) for Pompe disease along with supporting preclinical data. The results are scheduled to be presented at the symposium and will be made available on Denali's corporate website following the lifting of the event embargo. The FDA is currently conducting a Priority Review of the Biologics License Application for tividenofusp alfa, with a decision expected by April 5, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645676-en) on January 29, 2026, and is solely responsible for the information contained therein.